๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

The importance of Phase I/II trials in pediatric oncology

โœ Scribed by Craig A. MacArthur; Teresa Vietti

Publisher
Springer US
Year
1996
Tongue
English
Weight
285 KB
Volume
14
Category
Article
ISSN
0167-6997

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Phase I trial of trimetrexate in pediatr
Phase I trial of trimetrexate in pediatric solid tumors: A pediatric oncology group study
โœ Pappo, Alberto S. ;Vats, Tribhawan ;Williams, Thomas E. ;Bernstein, Mark ;Kamen, ๐Ÿ“‚ Article ๐Ÿ“… 1993 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 283 KB

## Abstract Trimetrexate (TMTX), a lipophilic antifol, was evaluated in a Pediatric Oncology Group (POG) Phase I trial in children with refractory solid tumors. TMTX was administered intravenously daily ร— 5 every three weeks. Starting dose was 6.4 mg/m^2^/day. Dose was escalated by 20% until the ma

Phase I trials in paediatric oncology โ€”
Phase I trials in paediatric oncology โ€” the European perspective
โœ E. J. Estlin; S. Ablett; D. R. Newell; I. J. Lewis; L. Lashford; A. D. J. Pearso ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› Springer US ๐ŸŒ English โš– 881 KB

The current recommendations for Phase I trials should allow more confident interpretation of the toxicity and efficacy of new agents by providing a framework for multicentre and international co-operation. An overview of the aims and designs of Phase I trials is presented, along with a summary of cu

Phase I trial of sargramostim in pediatr
Phase I trial of sargramostim in pediatric Crohn's disease
โœ Judith R. Kelsen; Joel Rosh; Mel Heyman; Harland S. Winter; George Ferry; Stanle ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 178 KB ๐Ÿ‘ 1 views

Background: Improving granulocyte function may represent an effective therapy for Crohn's disease (CD). We performed a Phase I-2 trial of sargramostim (SRG) in children with CD. Methods: This was multicenter, open-label study in 6-16-yearold patients with moderate to severely active CD. Patients re

Continual reassessment methods in phase
Continual reassessment methods in phase I trials of the combination of two drugs in oncology
โœ Andrew Kramar; Anne Lebecq; Emmanuel Candalh ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 153 KB ๐Ÿ‘ 2 views

Most phase I trials in oncology use standard methods for treating successive groups of patients with increasing doses in order to determine the maximum tolerated dose (MTD). These methods have been criticized because they treat many patients at suboptimal dose levels, and do not provide an accurate